Chronic Disease Research Group, Hennepin Healthcare Research Institute, 701 Park Avenue, Suite S4.100, Minneapolis, MN, 55415, USA.
Division of Nephrology, Hennepin Healthcare, Minneapolis, MN, USA.
BMC Endocr Disord. 2019 Aug 27;19(1):89. doi: 10.1186/s12902-019-0417-9.
Diabetes-related kidney disease is associated with end-stage renal disease and mortality, but opportunities remain to quantify its association with cardiovascular and non-cardiovascular morbidity outcomes.
We used the Truven Health MarketScan Commercial Claims and Encounters Database, 2010-2014, which includes specific health services records for employees and their dependents from a selection of large employers, health plans, and government and public organizations. We used administrative claims data to quantify the association between diabetes-related kidney disease and end-stage renal disease, myocardial infarction, congestive heart failure, stroke, and infections. Cox proportional hazard regression models were used to estimate adjusted hazard ratios of developing complications.
Among 2.2 million patients with diabetes, 7.1% had diabetes-related kidney disease: 13.5%, stage 1-2; 33.8%, stage 3; 13.2% stages 4-5; 39.5%, unknown stage. In multivariable Cox proportional hazard models adjusted for demographic characteristics, baseline comorbid conditions, and total hospital days during the baseline period, hazard ratios for each outcome increased with greater diabetes-related kidney disease severity (stage 1-2 vs. stage 4-5) compared with no diabetes-related kidney disease: myocardial infarction, 1.2 (95% confidence interval 1.1-1.4) and 3.1 (2.9-3.4); congestive heart failure, 1.7 (1.6-1.9) and 5.6 (5.3-5.8); stroke, 1.3 (1.2-1.5) and 2.3 (2.1-2.5); infection, 1.4 (1.3-1.5) and 2.9 (2.8-3.0). Among patients with stage 4-5 disease, 36-month cumulative incidence was nearly 22.8% for congestive heart failure, and 25.8% for infections.
Diabetes-related kidney disease appears to be formally diagnosed at a more advanced stage than might be expected, given clinical practice guidelines. Risks of cardiovascular and non-cardiovascular outcomes are high.
糖尿病相关肾脏疾病与终末期肾病和死亡率相关,但仍有机会量化其与心血管和非心血管发病率结局的关系。
我们使用了 Truven Health MarketScan 商业索赔和就诊数据库,该数据库涵盖了 2010 年至 2014 年期间来自一系列大型雇主、健康计划、政府和公共组织的员工及其家属的特定健康服务记录。我们使用管理索赔数据来量化糖尿病相关肾脏疾病与终末期肾病、心肌梗死、充血性心力衰竭、中风和感染之间的关联。Cox 比例风险回归模型用于估计发生并发症的调整后风险比。
在 220 万患有糖尿病的患者中,有 7.1%患有糖尿病相关肾脏疾病:13.5%为 1-2 期;33.8%为 3 期;13.2%为 4-5 期;39.5%为未知期。在多变量 Cox 比例风险模型中,根据人口统计学特征、基线合并症和基线期间的总住院天数进行调整,与无糖尿病相关肾脏疾病相比,每个结局的风险比随着糖尿病相关肾脏疾病严重程度的增加而增加(1-2 期与 4-5 期相比):心肌梗死 1.2(95%置信区间 1.1-1.4)和 3.1(2.9-3.4);充血性心力衰竭 1.7(1.6-1.9)和 5.6(5.3-5.8);中风 1.3(1.2-1.5)和 2.3(2.1-2.5);感染 1.4(1.3-1.5)和 2.9(2.8-3.0)。在患有 4-5 期疾病的患者中,充血性心力衰竭的 36 个月累积发生率接近 22.8%,感染的累积发生率为 25.8%。
考虑到临床实践指南,糖尿病相关肾脏疾病的正式诊断似乎比预期的更晚期。心血管和非心血管结局的风险很高。